BRIEF-Syndax Pharmaceuticals Reports Q4 Financial Results
BRIEF-Syndax Pharmaceuticals Reports Q4 Financial Results
簡介-Syndax製藥公司報告第四季度財務業績
March 8 (Reuters) - Syndax Pharmaceuticals Inc :
* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE
* Q4 LOSS PER SHARE $0.44
* Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA
* END OF YEAR CASH BALANCE OF $293.1 MILLION PROVIDES CASH RUNWAY INTO 2023
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE
* Q4 LOSS PER SHARE $0.44
* Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA
* END OF YEAR CASH BALANCE OF $293.1 MILLION PROVIDES CASH RUNWAY INTO 2023
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 8 (Reuters) - Syndax Pharmaceuticals Inc :
* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE
* Q4 LOSS PER SHARE $0.44
* Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA
* END OF YEAR CASH BALANCE OF $293.1 MILLION PROVIDES CASH RUNWAY INTO 2023
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月8日電-Syndax PharmPharmticals Inc:*Syndax PharmPharmticals報告2020年第四季度財務業績,並提供臨牀和業務最新情況*第四季度每股虧損0.44美元*第四季度每股收益預估-0.49美元-REFINITIV IBES數據*年終現金餘額2.931億美元為進入2023年提供了現金跑道Eikon的源文本:進一步的公司報道:(Reurs.Briefs@thomsonreurs.com;)
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!